Gene editing for advanced therapies: Governance, policy and society
Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system have ushered in a new era for gene editing and health innovation. The purpose of the E...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2018
|
| Schriftenreihe: | OECD Science, Technology and Industry Working Papers
no.2018/12 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system have ushered in a new era for gene editing and health innovation. The purpose of the Expert Meeting (6-7 July 2017, Federal Ministry of Education and Research, Berlin, Germany) was to explore the core scientific, legal, regulatory and societal challenges facing the responsible development and use of gene editing in somatic cells for advanced therapies. Experts noted that the trajectory of gene editing in research and development and the uptake of future therapies in the clinical setting remain unclear due to uncertainties in the scientific, regulatory, and economic landscapes. Many policy issues are also raised in the context of other emerging technologies. Governance must cope with a moving technical frontier and some level of uncertainty around risks and benefits. |
| Beschreibung: | 1 Online-Ressource (45 p.) |
| DOI: | 10.1787/8d39d84e-en |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-061258059 | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210204s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/8d39d84e-en |2 doi | |
| 035 | |a (DE-627-1)061258059 | ||
| 035 | |a (DE-599)KEP061258059 | ||
| 035 | |a (FR-PaOEC)8d39d84e-en | ||
| 035 | |a (EBP)061258059 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garden, Hermann |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Gene editing for advanced therapies |b Governance, policy and society |c Hermann, Garden and David, Winickoff |
| 264 | 1 | |a Paris |b OECD Publishing |c 2018 | |
| 300 | |a 1 Online-Ressource (45 p.) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Science, Technology and Industry Working Papers |v no.2018/12 | |
| 520 | |a Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system have ushered in a new era for gene editing and health innovation. The purpose of the Expert Meeting (6-7 July 2017, Federal Ministry of Education and Research, Berlin, Germany) was to explore the core scientific, legal, regulatory and societal challenges facing the responsible development and use of gene editing in somatic cells for advanced therapies. Experts noted that the trajectory of gene editing in research and development and the uptake of future therapies in the clinical setting remain unclear due to uncertainties in the scientific, regulatory, and economic landscapes. Many policy issues are also raised in the context of other emerging technologies. Governance must cope with a moving technical frontier and some level of uncertainty around risks and benefits. | ||
| 650 | 4 | |a Science and Technology | |
| 650 | 4 | |a Industry and Services | |
| 700 | 1 | |a Winickoff, David |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/8d39d84e-en |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-061258059 |
|---|---|
| _version_ | 1804748658657198080 |
| adam_text | |
| any_adam_object | |
| author | Garden, Hermann |
| author2 | Winickoff, David |
| author2_role | ctb |
| author2_variant | d w dw |
| author_facet | Garden, Hermann Winickoff, David |
| author_role | aut |
| author_sort | Garden, Hermann |
| author_variant | h g hg |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC |
| ctrlnum | (DE-627-1)061258059 (DE-599)KEP061258059 (FR-PaOEC)8d39d84e-en (EBP)061258059 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/8d39d84e-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02155cam a22003612 4500</leader><controlfield tag="001">ZDB-13-SOC-061258059</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121324.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210204s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/8d39d84e-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)061258059</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP061258059</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)8d39d84e-en</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)061258059</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Garden, Hermann</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Gene editing for advanced therapies</subfield><subfield code="b">Governance, policy and society</subfield><subfield code="c">Hermann, Garden and David, Winickoff</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (45 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Science, Technology and Industry Working Papers</subfield><subfield code="v">no.2018/12</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system have ushered in a new era for gene editing and health innovation. The purpose of the Expert Meeting (6-7 July 2017, Federal Ministry of Education and Research, Berlin, Germany) was to explore the core scientific, legal, regulatory and societal challenges facing the responsible development and use of gene editing in somatic cells for advanced therapies. Experts noted that the trajectory of gene editing in research and development and the uptake of future therapies in the clinical setting remain unclear due to uncertainties in the scientific, regulatory, and economic landscapes. Many policy issues are also raised in the context of other emerging technologies. Governance must cope with a moving technical frontier and some level of uncertainty around risks and benefits.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Science and Technology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Industry and Services</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winickoff, David</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/8d39d84e-en</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-061258059 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-16T15:07:23Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (45 p.) |
| psigel | ZDB-13-SOC |
| publishDate | 2018 |
| publishDateSearch | 2018 |
| publishDateSort | 2018 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Science, Technology and Industry Working Papers |
| spelling | Garden, Hermann VerfasserIn aut Gene editing for advanced therapies Governance, policy and society Hermann, Garden and David, Winickoff Paris OECD Publishing 2018 1 Online-Ressource (45 p.) Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Science, Technology and Industry Working Papers no.2018/12 Gene editing aims to modify the genetic sequence at a precise genomic location. Recent breakthroughs in gene editing techniques such as the clustered regularly interspaced short palindromic repeats (CRISPR) system have ushered in a new era for gene editing and health innovation. The purpose of the Expert Meeting (6-7 July 2017, Federal Ministry of Education and Research, Berlin, Germany) was to explore the core scientific, legal, regulatory and societal challenges facing the responsible development and use of gene editing in somatic cells for advanced therapies. Experts noted that the trajectory of gene editing in research and development and the uptake of future therapies in the clinical setting remain unclear due to uncertainties in the scientific, regulatory, and economic landscapes. Many policy issues are also raised in the context of other emerging technologies. Governance must cope with a moving technical frontier and some level of uncertainty around risks and benefits. Science and Technology Industry and Services Winickoff, David MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/8d39d84e-en Volltext |
| spellingShingle | Garden, Hermann Gene editing for advanced therapies Governance, policy and society Science and Technology Industry and Services |
| title | Gene editing for advanced therapies Governance, policy and society |
| title_auth | Gene editing for advanced therapies Governance, policy and society |
| title_exact_search | Gene editing for advanced therapies Governance, policy and society |
| title_full | Gene editing for advanced therapies Governance, policy and society Hermann, Garden and David, Winickoff |
| title_fullStr | Gene editing for advanced therapies Governance, policy and society Hermann, Garden and David, Winickoff |
| title_full_unstemmed | Gene editing for advanced therapies Governance, policy and society Hermann, Garden and David, Winickoff |
| title_short | Gene editing for advanced therapies |
| title_sort | gene editing for advanced therapies governance policy and society |
| title_sub | Governance, policy and society |
| topic | Science and Technology Industry and Services |
| topic_facet | Science and Technology Industry and Services |
| url | https://doi.org/10.1787/8d39d84e-en |
| work_keys_str_mv | AT gardenhermann geneeditingforadvancedtherapiesgovernancepolicyandsociety AT winickoffdavid geneeditingforadvancedtherapiesgovernancepolicyandsociety |